ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 168

IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients

Irene Cecchi1, Massimo Radin2, Elena Rubini3, Ana Suárez4, Dario Roccatello5, Savino Sciascia6 and Javier Rodríguez-Carrio7, 1Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 2Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, 4Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, 5Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, 6Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, 7Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: , , ,

Session Information

Date: Sunday, October 21, 2018

Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of cardiovascular disease in autoimmune conditions. Nevertheless, the association between anti-HDL and clinical features of APS remains unclear.

Methods:

This cross-sectional study included 60 thrombotic APS patients and 20 healthy donors (HDs). Clinical data were retrospectively collected (Figure 1). Serum levels of total IgG, IgG anti-HDL antibodies and complete aPL profile were assessed, including lupus anticoagulant, anti-cardiolipin, anti-β2glycoprotein I, and anti-phosphatidylserine/prothrombin antibodies.

Results:

43 patients (72%) were primary APS and 17 patients (28%) had a concomitant diagnosis of autoimmune disease. Thirty APS patients (50%) presented previous arterial events and 37 (61%) venous events. Higher levels of IgG anti-HDL were found in APS patients compared to HDs [mean 46 (±70) vs. 14 (±13) AU, respectively; p <0.001], even after correcting for total IgG levels [mean 13 (±16) vs. 4.6 (±5), respectively; p <0.001]. No association with traditional cardiovascular risk factors, except for smoking habit (p <0.0001) was found. No differences in anti-HDL levels were observed between patients with primary APS and those with a concomitant autoimmune disease (p >0.050). Patients who experienced at least one arterial event had significantly higher levels of anti-HDL antibodies when compared to patients with history of venous thrombosis [mean 53 (SD ±94) vs. mean 34 (SD ±29), respectively; p =0.046] (Figure 2). This difference became stronger when adjusting for total IgG levels [anti-HDL/IgG: mean 13.1 (SD ±16.7) vs. mean 9.5 (SD ±6.6); p =0.007]. In addition, patients tested positive for aPS/PT (IgG/IgM) antibodies had significantly higher levels of anti-HDL antibodies [mean 53.1 (SD ±81.1) vs. mean 20.7 (SD ±17.6), p =0.045]. The levels of IgG anti-HDL antibodies were not influenced by pharmacological treatments (all p >0.050).

Conclusion:

Our study demonstrates that thrombotic APS patients have higher levels of IgG anti-HDL antibodies, supporting the emerging role of these autoantibodies in APS setting. Moreover, our findings suggest that anti-HDL represent a promising tool for risk management and assessment and a potential biomarker for lipid dysfunction and arterial thrombotic events. 

Figure 1

Figure 2

 

 

Disclosure: I. Cecchi, None; M. Radin, None; E. Rubini, None; A. Suárez, None; D. Roccatello, None; S. Sciascia, None; J. Rodríguez-Carrio, None.

To cite this abstract in AMA style:

Cecchi I, Radin M, Rubini E, Suárez A, Roccatello D, Sciascia S, Rodríguez-Carrio J. IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/igg-anti-high-density-lipoproteins-antibodies-discriminate-between-arterial-and-venous-events-in-thrombotic-antiphospholipid-syndrome-patients/. Accessed .

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/igg-anti-high-density-lipoproteins-antibodies-discriminate-between-arterial-and-venous-events-in-thrombotic-antiphospholipid-syndrome-patients/